Cellular cycle anomalies for targeting oncology and...

Details Cellular cycle anomalies for targeting oncology and... Cellular cycle anomalies for targeting oncology and...

2008-03-12

2011-10-18

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S326000, C530S327000, C530S300000, C514S021500

Reexamination Certificate

active

08039439

ABSTRACT:
The present invention relates to the field of medicine and biology. It concerns a novel test for screening and for therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. It is a diagnostic test and a prognostic test for various cancers (breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, glioblastoma, sarcoma, leukemia, etc.) and therapeutics solutions for specific neurodegenerative diseases. More particularly, the invention concerns the use of the LIV21 protein, LIV21 gene and of derivatives thereof as diagnostic and prognostic markers for cancers. The invention therefore concerns the detection of the LIV21 protein with a kit comprising LIV21-specific antibodies.

REFERENCES:
Wells, J.A. (1990). Additivity of mutational effects in proteins. Biochemistry. 29(37):8509-8517.
Ngo et al. (1994). Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 491-495.

Affiliated with

Also associated with

Rating

Cellular cycle anomalies for targeting oncology and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cellular cycle anomalies for targeting oncology and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cellular cycle anomalies for targeting oncology and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4273461